Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the veterans affairs HDL intervention trial (VA-HIT)

Atherosclerosis

Volumn 194, Issue 1, 2007, Pages 169-174

  Georgopoulos, Angeliki ^a   Bloomfield, Hanna ^a   Collins, Dorothea ^b   Brousseau, Margaret E ^c   Ordovas, Jose M ^c   O'Connor, John J ^c   Robins, Sander J ^d   Schaefer, Ernest J ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c TUFTS UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular risk; Diabetes; FABP2; Polymorphisms

Indexed keywords

ALANINE; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 2; HIGH DENSITY LIPOPROTEIN; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; CODON; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE; VETERAN;

AGED; ANTILIPEMIC AGENTS; CODON; DIABETES MELLITUS; DYSLIPIDEMIAS; FATTY ACID-BINDING PROTEINS; GEMFIBROZIL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RISK FACTORS; STROKE; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 34648844160     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.07.022     Document Type: Article

References (38)

1. Lowe J.B., Sacchettini J.C., Laposata M., et al. Expression of rat intestinal fatty acid-binding protein in Escherichia coli. J Biol Chem 262 (1987) 5931-5937
2. Baier L.J., Sacchettini J.C., Knowler W.C., et al. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation and insulin resistance. J Clin Invest 95 (1995) 1281-1287
3. Ito K., Nakatani K., Fujii M., et al. Codon 54 polymorphism of the fatty acid binding protein gene and insulin resistance in the Japanese population. Diab Med 16 (1999) 119-124
4. Rissanen J., Pihlajamäki J., Heikkinen S., et al. The Ala54Thr polymorphism of the fatty acid binding protein 2 gene does not influence insulin sensitivity in Finnish nondiabetic and NIDDM subjects. Diabetes 46 (1997) 711-712
5. Baier L.J., Bogardus C., Sacchettini J.C., et al. A polymorphism in the human intestinal fatty acid binding protein alters fatty acid transport across Caco-2 cells. J Biol Chem 271 (1996) 10892-10896
6. Levy E., Menard D., Delvin E., et al. The polymorphism at codon 54 of the FABP2 gene increases fat absorption in human intestinal explants. J Biol Chem 276 (2001) 39679-39684
7. Georgopoulos A., Aras O., and Tsai Y.M. Codon-54 Polymorphism of the fatty acid-binding protein 2 gene is associated with elevation of fasting and postprandial triglyceride in type 2 diabetes. J Clin Endocrinol Metab 85 (2000) 3155-3160
8. Georgopoulos A. Postprandial triglyceride metabolism in diabetes mellitus. Clin Cardiol 22 Suppl. II (1999) 28-33
9. Garcia M.J., McNamara P.M., Gordon T., et al. Morbidity and mortality in diabetics in the Framingham population: sixteen year follow up study. Diabetes 23 (1974) 105-112
10. West K.M., Ahyja M.M.S., Bennett P.H., et al. The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 6 (1983) 361-369
11. Rubins H.B., Robins S.J., Iwane M.K., et al. Rationale and design of the Department of veterans affairs high-density lipoprotein cholesterol intervention trial (VA-HIT) for secondary prevention of coronary artery disease in men with low high density lipoprotein cholesterol and desirable low density lipoprotein cholesterol. Am J Cardiol 71 (1993) 45-52
12. Bloomfield-Rubins H., Davenport J., Babikian V., et al. Reduction of stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. The veterans affairs HDL intervention trial (VA-HIT). Circulation 103 (2001) 2828-2833
13. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary artery disease in men with low high density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
14. Galluzi J.R., and Ordovas J.M. Genotyping method for point mutation detection in the intestinal fatty acid binding protein, using fluorescent probes. Clin Chem 45 (1999) 1092-1094
15. Cox D.R. Regression models and life tables. J Roy Stat Soc [B] 34 (1972) 187-202
16. Saarinen L., Pulkkinen A., Kareinen A., et al. Variants of the fatty acid-binding protein 2 gene are not associated with coronary heart disease in nondiabetic subjects and in patients with NIDDM. Diabetes Care 21 (1998) 849-850
17. Carlsson M., Orho-Melander M., Hedenbro J., et al. The t 54 allelle of the intestinal fatty acid-binding protein 2 is associated with parental history of stroke. J Clin Endocrinol Metab 85 (2000) 2801-2804
18. Wanby P., Palmquist P., Ryden I., et al. The FABP2 gene polymorphism in cerebrovascular disease. Acta Neurol Scand 110 (2004) 355-360
19. Wanby P., Palmquist P., Brudin L., et al. Genetic variation of the intestinal fatty acid-binding protein 2 gene in carotid atherosclerosis. Vasc Med 10 (2005) 103-108
20. Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27 (2004) 1496-1504
21. Shepherd J. Diabetic dyslipidemia and atherosclerosis. Schweiz Med Wochenshr 124 (1994) 1933-1937
22. Berthier M.T., Couillard C., Prud'homme D., et al. Effects of the FABP2 A54T mutation on triglyceride metabolism in viscerally obese men. Obes Res 9 (2001) 668-675
23. Hegele R.A., Harris S.B., Hanley A.J.G., et al. Genetic variation of intestinal fatty acid-binding protein is associated with variation in body mass in aboriginal Canadians. J Clin Endocrinol Metab 81 (1996) 4334-4337
24. Mitchell B.D., Kammerer M., O'Connell P., et al. Evidence for linkage of postchallenge insulin levels with intestinal fatty acid-binding protein (FABP2) in Mexican-Americans. Diabetes 44 (1995) 1046-1053
25. Yamada K., Yuan X., Ishiyama S., et al. Association between Ala54Thr substitution of the fatty acid-binding protein gene 2 with insulin resistance and intra-abdominal fat thickness in Japanese men. Diabetologia 40 (1997) 706-710
26. Galluzzi J.R., Cupples L.A., Meigs J.B., et al. Association of the Ala54-Thr polymorphism in the intestinal fatty acid-binding protein with 2-h postchallenge insulin levels in the Framingham Offspring Study. Diabetes Care 24 (2001) 1161-1166
27. Hsien-Hsien L., Coresh J., Shuldiner A.R., et al. Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity and hyperinsulinemia in African-Americans. Diabetes 48 (1999) 1868-1872
28. Hayakawa T., Nagai Y., Nohara E., et al. Variation of the fatty acid binding protein 2 gene is not associated with obesity and insulin resistance in Japanese subjects. Metabolism 48 (1999) 655-657
29. Georgopoulos A., Aras O., Noutsou M., et al. Unlike type 2 diabetes, type 1 does not interact with the codon 54 polymorphism of the fatty acid binding protein 2 gene. J Clin Endocrinol Metab 87 (2002) 3735-3739
30. Erkkila A.T., Lindi V., Lehto S., et al. Variation in the fatty acid binding protein 2 gene is not associated with markers of metabolic syndrome in patients with coronary heart disease. Nutr Metab Cardiovasc Dis 12 (2002) 53-59
31. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
32. Robins S.J. Targeting low high density lipoprotein cholesterol for therapy: lessons from the veterans affairs high density lipoprotein trial. Am J Cardiol 88 suppl. (2001) 19N-23N
33. Weiss E.P., Brown M.D., Shuldiner A.R., et al. Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effects. Physiol Genomics 10 (2001) 145-157
34. Canani L.H., Capp C.P.K., Ng D., et al. The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes. Diabetes 54 (2005) 3326-3330
35. Yamada Y., Ichihara S., Izawa H., et al. Genetic risk for coronary artery disease in individuals with or without type 2 diabetes. Mol Genet Metab 81 (2004) 282-290
36. Horibe H., Yamada Y., Ichihara S., et al. Genetic risk of restenosis after coronary balloon angioplasty. Atherosclerosis 174 (2004) 181-187
37. Rubins H.B., Robins S.J., Collins D., et al. Diabetes, plasma insulin and cardiovascular disease: subgroup analysis from the department of veterans affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162 (2002) 2597-2604
38. McMahon S., Peto R., Cutler J., et al. Blood pressure, stroke and coronary heart disease: prolonged differences in blood pressure: prospective observational studies corrected for regression dilution bias. Lancet 335 (1990) 765-774